Branislav Jeremic

Branislav Jeremic

Auto-generated profile, based on publicly available information

Branislav Jeremic

Faculty of Medicine,University ofKragujevac, Kragujevac, Serbia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
LKLucyna Kepka
Lucyna Kepka
ASArkadiusz Sprawka
Arkadiusz Sprawka
FCFrancesc Casas
Francesc Casas
SASherif Abdel-Wahab
Sherif Abdel-Wahab
JAJaiprakash Agarwal
Jaiprakash Agarwal
BJBranislav Jeremic
Branislav Jeremic
The combination of radiotherapy and chemotherapy is considered to be a standard approach for patients with locally advanced, stage III non-small-cell lung cancer. The current state of the art of combined radiochemotherapy supported by evidence-based data is presented. As shown in the meta-analyses, the concurrent radiochemotherapy gives a superior outcome in terms of survival compared with sequential delivery of both modalities. This is obtained at the expense of higher toxicity, which makes further intensification of radiochemotherapy challenging. Eligibility of patients with non-small-cell lung cancer for such an approach is limited. The new methods to improve treatment results, such as selection of proper strategies, incorporation of molecular agents into combined treatment and radiotherapy technique modifications are discussed.

30 September 2012 in International Journal of Precision Engineering and Manufacturing
Verified
Journal Article
Closed access
PDF file
BTBranko Tadic
Branko Tadic
BJBranislav Jeremic
Branislav Jeremic
PTPetar Todorovic
Petar Todorovic
DVDjordje Vukelic
Djordje Vukelic
UPUros Proso
Uros Proso
IBIgor Budak
Igor Budak


24 November 2009
Verified
Book Chapter
Closed access
BJBranislav Jeremic
Branislav Jeremic
FCFrancesc Casas
Francesc Casas
LWLuhua Wang
Luhua Wang
BPBranislav Perin
Branislav Perin
Patients with extensive disease small cell lung cancer (ED-SCLC) represent approximately one-third of all SCLC patients. For these patients, chemotherapy (CHT) is the standard treatment of choice. With CHT given alone, however, there is not a high risk of distant progression, but also progression within the thorax and brain frequently occurs, even in patients achieving a response to CHT. To improve poor figures obtained with CHT alone and address important issue of intrathoracic tumor control and it relationship to overall survival, thoracic radiation therapy (TRT) was introduced with a curative intent in a prospective randomized trial by Jeremic et al (1988-1993). In that trial CHT alone was compared with CHT followed by TRT, and in both groups by a prophylactic cranial irradiation. This trial showed that TRT can offer an improvement on local control that leads to an improvement in overall survival. Toxicity was acceptable, while multivariate analysis identified number of metastasis as an independent prognosticator of outcome. Based on the data of this trial, researchers in the USA and Europe will undergo two prospective trials addressing the issue of TRT in ED-SCLC.


1 June 1992 in Journal of Chemotherapy
Verified
Journal Article
Closed access
BJB. Jeremic
B. Jeremic
DZD.J. Zivic
D.J. Zivic
LDL.J. Djuric
L.J. Djuric
LML.J. Mijatovic
L.J. Mijatovic